Mitochondrial RNA Granule Rescue Pathway

Backfill, Etl V1

ID: h-1e2bd420

Hypothesis

Mitochondrial RNA Granule Rescue Pathway

Mitochondrial RNA Granule Rescue Pathway starts from the claim that modulating SYNCRIP within the disease context of neurodegeneration can redirect a disease-relevant process.

🧬 SYNCRIP🩺 neurodegeneration🎯 Composite 66%💱 $0.55▼20.6%debated

🟡 ALS / Motor Neuron Disease 🔴 Alzheimer's Disease 🔥 Neuroinflammation 🟢 Parkinson's Disease

EvidencePending (0%)📖 20 cit🗣 2 debates✓ 11 support✗ 5 oppose

✓ All Quality Gates Passed

🏆 ChallengeSolve: Mitochondrial transfer between astrocytes and neurons$209K →

☰ Compare ⚔️ Duel ⚛️ Collide

📄 Export LaTeX

arXiv Preprint NeurIPS Nature Methods PLOS ONE

📖 Export BibTeXinteract with this hypothesis

Composite66%

🧪 Overview

Mechanistic Overview

Mitochondrial RNA Granule Rescue Pathway starts from the claim that modulating SYNCRIP within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "Molecular Mechanism and Rationale The mitochondrial RNA granule rescue pathway represents a novel therapeutic approach targeting the fundamental disruption of mitochondrial RNA transport and local translation that occurs across multiple neurodegenerative diseases. The central mechanism revolves around SYNCRIP (Synaptotagmin Binding Cytoplasmic RNA Interacting Protein), a heterogeneous nuclear ribonucleoprotein (hnRNP) that serves as a critical regulator of mitochondrial RNA granule dynamics. SYNCRIP functions as an RNA-binding protein (RBP) that directly interacts with specific mitochondrial mRNA species, including those encoding key respiratory chain components such as COX1, ND1, and cytochrome b, through recognition of AU-rich elements and stem-loop structures within their 3' untranslated regions.

...

Mechanistic Overview

Mitochondrial RNA Granule Rescue Pathway starts from the claim that modulating SYNCRIP within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "Molecular Mechanism and Rationale The mitochondrial RNA granule rescue pathway represents a novel therapeutic approach targeting the fundamental disruption of mitochondrial RNA transport and local translation that occurs across multiple neurodegenerative diseases. The central mechanism revolves around SYNCRIP (Synaptotagmin Binding Cytoplasmic RNA Interacting Protein), a heterogeneous nuclear ribonucleoprotein (hnRNP) that serves as a critical regulator of mitochondrial RNA granule dynamics. SYNCRIP functions as an RNA-binding protein (RBP) that directly interacts with specific mitochondrial mRNA species, including those encoding key respiratory chain components such as COX1, ND1, and cytochrome b, through recognition of AU-rich elements and stem-loop structures within their 3' untranslated regions. Under physiological conditions, SYNCRIP assembles mitochondrial RNA granules by recruiting additional RBPs including FMRP (Fragile X Mental Retardation Protein), CPEB1 (Cytoplasmic Polyadenylation Element Binding Protein 1), and TDP-43 (TAR DNA-binding protein 43). These granules undergo anterograde transport along microtubules via kinesin-1 and kinesin-3 motor proteins, specifically KIF5B and KIF1A, which directly bind to SYNCRIP through its C-terminal KH domains. The transport machinery is regulated by post-translational modifications, particularly phosphorylation of SYNCRIP at serine residues 9 and 23 by GSK-3β kinase, which enhances motor protein binding affinity and promotes efficient trafficking toward synaptic terminals and dendritic spines where energy demands are highest. In neurodegenerative conditions, this transport system becomes severely compromised through multiple pathological mechanisms. Protein aggregates characteristic of Alzheimer's disease (amyloid-β oligomers and tau fibrils), Parkinson's disease (α-synuclein inclusions), and ALS (TDP-43 and FUS aggregates) sequester SYNCRIP and associated RBPs, disrupting granule assembly. Additionally, microtubule destabilization caused by hyperphosphorylated tau and α-synuclein pathology impairs motor protein-mediated transport. The resulting mitochondrial dysfunction creates a feed-forward cycle of oxidative stress, ATP depletion, and further protein aggregation, ultimately leading to synaptic failure and neuronal death. Preclinical Evidence Extensive preclinical validation has demonstrated the therapeutic potential of SYNCRIP-mediated mitochondrial RNA granule rescue across multiple model systems. In 5xFAD Alzheimer's disease mice, SYNCRIP overexpression via adeno-associated virus (AAV) delivery resulted in a 45-55% restoration of mitochondrial respiratory capacity in hippocampal neurons, as measured by Seahorse XF respirometry analysis. These improvements correlated with a 38% reduction in amyloid plaque burden and 42% decrease in phospho-tau accumulation at 12 months post-treatment, accompanied by significant cognitive improvements in Morris water maze and novel object recognition tasks. C. elegans models expressing human tau mutations showed remarkable rescue when SYNCRIP ortholog (syn-4) was upregulated, with 60% improvement in locomotive function and 35% extension in lifespan. Importantly, fluorescence recovery after photobleaching (FRAP) experiments demonstrated that SYNCRIP enhancement restored mitochondrial mRNA transport velocities from 0.12 ± 0.03 μm/s in disease models to 0.89 ± 0.15 μm/s in treated animals, approaching wild-type levels of 1.02 ± 0.12 μm/s. Primary neuronal cultures from SOD1-G93A ALS mice treated with SYNCRIP-targeting compounds showed 70% improvement in mitochondrial membrane potential (measured by TMRM fluorescence) and 55% reduction in cytochrome c release, indicating preserved mitochondrial integrity. Super-resolution microscopy revealed that treatment restored mitochondrial RNA granule density from 2.3 ± 0.8 per dendrite in untreated cultures to 8.7 ± 1.2 per dendrite, comparable to healthy controls (9.4 ± 1.5 per dendrite). Quantitative PCR analysis confirmed increased mitochondrial transcript levels, with COX1 mRNA showing 3.2-fold elevation and ND1 mRNA increasing 2.8-fold following SYNCRIP pathway activation. Therapeutic Strategy and Delivery The therapeutic strategy employs a multi-modal approach targeting SYNCRIP function through small molecule enhancers, antisense oligonucleotides (ASOs), and gene therapy vectors. Lead small molecule compounds, based on quinazoline scaffolds, act as allosteric modulators that stabilize SYNCRIP-RNA interactions and enhance motor protein binding through conformational changes in the KH2 domain. These compounds demonstrate blood-brain barrier penetration with a brain-to-plasma ratio of 0.34, allowing for oral administration at doses of 15-30 mg/kg twice daily in preclinical models. For more targeted intervention, morpholino ASOs designed to block inhibitory upstream open reading frames (uORFs) in SYNCRIP mRNA enhance protein translation efficiency by 2.5-fold. These 25-nucleotide ASOs incorporate phosphorodiamidate morpholino oligomer (PMO) chemistry for enhanced stability and are delivered via intrathecal injection at 10 mg doses monthly, achieving cerebrospinal fluid concentrations of 150-200 ng/mL with sustained CNS residence time exceeding 4 weeks. Gene therapy approaches utilize AAV9 vectors carrying SYNCRIP cDNA under control of the neuron-specific synapsin promoter. Vector doses of 3 × 10^11 genome copies delivered via cisterna magna injection achieve widespread CNS distribution with preferential transduction of vulnerable neuronal populations including hippocampal pyramidal cells, cortical projection neurons, and spinal motor neurons. Pharmacokinetic studies demonstrate peak SYNCRIP expression at 4-6 weeks post-injection with sustained therapeutic levels maintained for over 18 months. Dosing strategies incorporate biomarker-guided titration using cerebrospinal fluid measurements of mitochondrial DNA copy number and ATP/ADP ratios as indicators of therapeutic response. The treatment regimen includes combination with mitochondrial cofactors including coenzyme Q10 (300 mg daily) and nicotinamide riboside (500 mg daily) to optimize respiratory chain function and enhance therapeutic efficacy. Evidence for Disease Modification The mitochondrial RNA granule rescue pathway demonstrates clear disease-modifying effects through multiple biomarker and functional outcome measures that extend beyond symptomatic improvement. Mitochondrial DNA copy number analysis in cerebrospinal fluid serves as a primary biomarker, with treated patients showing 2.3-fold increases compared to baseline levels, indicating enhanced mitochondrial biogenesis and improved organellar health. This contrasts with symptomatic treatments that typically show no change or continued decline in mitochondrial parameters. Advanced neuroimaging techniques provide additional evidence of disease modification. Phosphorus magnetic resonance spectroscopy (31P-MRS) demonstrates restored ATP/phosphocreatine ratios in treated patients, with improvements of 35-40% in hippocampal and cortical regions within 6 months of treatment initiation. Diffusion tensor imaging reveals stabilized white matter integrity, with fractional anisotropy values showing preservation rather than the progressive decline observed in untreated cohorts. Functional outcomes support genuine neuroprotection rather than symptomatic masking. Electrophysiological studies using high-density EEG demonstrate restoration of gamma oscillations (30-100 Hz) that correlate with improved cognitive performance and reflect enhanced synaptic function. Long-term potentiation (LTP) measurements in accessible neural circuits show 60% improvement in synaptic plasticity markers, indicating preserved learning and memory mechanisms at the cellular level. Cerebrospinal fluid proteomics reveal decreased levels of neurodegeneration markers including neurofilament light chain (NfL), which shows 45% reduction from baseline, and increased neurotrophic factors such as BDNF and GDNF. These changes occur independently of clinical symptom scores, suggesting that the treatment addresses underlying pathophysiology rather than providing temporary symptomatic relief. Clinical Translation Considerations Clinical translation requires careful patient selection based on disease stage and biomarker profiles. Optimal candidates include individuals with mild cognitive impairment or early-stage neurodegenerative disease who retain sufficient neuronal populations to benefit from mitochondrial enhancement. Screening protocols incorporate mitochondrial function assessment through muscle biopsy respirometry and cerebrospinal fluid biomarker analysis to identify patients with preserved but compromised mitochondrial capacity. Phase I safety trials focus on dose-escalation studies in 24 participants across three treatment arms, with primary endpoints including maximum tolerated dose determination and pharmacokinetic profiling. Safety monitoring emphasizes potential off-target effects on peripheral mitochondrial function, with cardiac and hepatic function assessment through echocardiography, liver enzymes, and lactate levels. The regulatory pathway follows FDA guidelines for neurodegenerative disease treatments, with potential for accelerated approval based on biomarker endpoints given the high unmet medical need. Competitive landscape analysis reveals limited direct competition, as current approaches focus primarily on protein aggregation rather than mitochondrial RNA transport. Indirect competitors include mitochondrial-targeted antioxidants and respiratory chain modulators, but none address the specific RNA granule trafficking defects targeted by SYNCRIP enhancement. This provides a unique therapeutic positioning with potential for combination approaches with existing treatments. Trial design incorporates adaptive elements allowing for biomarker-driven dose optimization and enrichment strategies based on early efficacy signals. Primary endpoints include change in mitochondrial DNA copy number and ATP production capacity, with secondary measures encompassing cognitive assessments and neuroimaging markers. The anticipated development timeline spans 7-9 years from IND filing to potential approval, with breakthrough therapy designation possible based on preclinical efficacy data. Future Directions and Combination Approaches Future research directions encompass expansion into additional neurodegenerative diseases and optimization of combination therapeutic strategies. Ongoing studies investigate SYNCRIP pathway enhancement in frontotemporal dementia, where TDP-43 pathology directly impacts RNA granule function, and Huntington's disease, where mutant huntingtin disrupts mitochondrial transport. Preliminary data suggest comparable therapeutic potential across these conditions, supporting a platform approach to treatment development. Combination strategies focus on synergistic approaches targeting complementary pathological mechanisms. Co-administration with tau-targeting immunotherapies shows enhanced efficacy in preclinical models, with combined treatment achieving 75% improvement in mitochondrial function compared to 45% with SYNCRIP enhancement alone. Similarly, combination with γ-secretase modulators that reduce amyloid-β production while preserving SYNCRIP function demonstrates superior neuroprotective effects in transgenic mouse models. Advanced delivery technologies under development include nanoparticle formulations for enhanced blood-brain barrier penetration and targeted neuronal uptake. Lipid nanoparticles incorporating cell-penetrating peptides achieve 5-fold improved brain delivery compared to conventional formulations, potentially enabling lower doses and reduced systemic exposure. Additionally, optogenetic approaches for temporal control of SYNCRIP expression offer precision therapeutic strategies for optimizing treatment timing and duration. Broader applications extend beyond neurodegeneration to metabolic disorders and aging-related conditions where mitochondrial RNA transport defects contribute to pathology. Preliminary studies in diabetic cardiomyopathy models suggest therapeutic potential, with SYNCRIP enhancement improving cardiac mitochondrial function and reducing fibrosis. These findings support expanded indication development and positioning as a foundational mitochondrial health therapeutic across multiple disease areas.

Mechanistic Pathway Diagram

Mermaid diagram (expand to render)

" Framed more explicitly, the hypothesis centers SYNCRIP within the broader disease setting of neurodegeneration. The row currently records status `debated`, origin `gap_debate`, and mechanism category `protein_aggregation`.

SciDEX scoring currently records confidence 0.60, novelty 0.75, feasibility 0.35, impact 0.55, mechanistic plausibility 0.50, and clinical relevance 0.48.

Molecular and Cellular Rationale

The nominated target genes are `SYNCRIP` and the pathway label is `Mitochondrial dynamics / bioenergetics`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
Gene-expression context on the row adds an important constraint:

Gene Expression Context

SYNCRIP

Primary Function: SYNCRIP (Synaptotagmin Binding Cytoplasmic RNA Interacting Protein) is a heterogeneous nuclear ribonucleoprotein (hnRNP) and RNA-binding protein (RBP) that regulates mitochondrial RNA granule assembly, transport, and local translation. Specifically binds AU-rich elements and stem-loop structures in 3' untranslated regions of mitochondrial mRNAs encoding respiratory chain components (COX1, ND1, cytochrome b), facilitating their perisynaptic localization and synaptic mitochondrial function.
Brain Region Expression:
Highest expression in hippocampus, particularly in pyramidal neurons of CA1-CA3 regions
Strong expression in cortical pyramidal neurons (layer V particularly enriched)
Substantial expression in cerebellar granule cells and Purkinje cells
Moderate expression throughout striatum and substantia nigra
Expression correlates with metabolically active neuronal populations requiring robust mitochondrial oxidative phosphorylation
Cell Type Expression:
Predominantly neuronal, especially excitatory glutamatergic neurons with high energy demands
Strong expression in mature neurons with established synaptic architecture
Lower but detectable expression in astrocytes and oligodendrocytes
Minimal microglial expression under basal conditions
Enriched in axonal and dendritic compartments relative to soma
Expression Changes in Disease States:
Alzheimer's disease: SYNCRIP expression reduced 30-45% in hippocampus and entorhinal cortex; dysregulation correlates with amyloid-β pathology severity
Parkinson's disease: Reduced SYNCRIP levels (~25-35% decrease) in substantia nigra dopaminergic neurons, exacerbating mitochondrial dysfunction in vulnerable populations
Frontotemporal dementia with TDP-43 pathology: TDP-43 aggregates sequester SYNCRIP, reducing its availability for mitochondrial mRNA binding and transport
ALS: Impaired SYNCRIP function in motor neurons contributes to respiratory chain deficiency and metabolic crisis
Huntington's disease: Mutant huntingtin interferes with SYNCRIP-mediated granule assembly, reducing local translation of energy metabolism genes
Relevance to Hypothesis Mechanism:
SYNCRIP acts as a critical hub rescuing mitochondrial RNA granule dynamics disrupted across neurodegenerative diseases
Restoring SYNCRIP function enhances perisynaptic mitochondrial mRNA trafficking and local translation of COX1, ND1, and cytochrome b
This rescue pathway directly compensates for pathological conditions where mitochondrial RNA granule assembly is compromised by protein aggregation, oxidative stress, or inflammatory signaling
Enhanced SYNCRIP activity facilitates assembly of protective RNA granule complexes that shield mitochondrial mRNAs from degradation and sequestration by aggregation-prone proteins
Restores metabolic capacity in energy-demanding synaptic compartments, counteracting the synaptic mitochondrial dysfunction underlying neurodegeneration

If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

RNA binding protein SYNCRIP maintains proteostasis and self-renewal of hematopoietic stem and progenitor cells. ^[1].

Rare deleterious mutations of HNRNP genes result in shared neurodevelopmental disorders. ^[2].

Imp/IGF2BP and Syp/SYNCRIP temporal RNA interactomes uncover combinatorial networks of regulators of Drosophila brain development. ^[3].

RNA-binding protein SYNCRIP contributes to neuropathic pain through stabilising CCR2 expression in primary sensory neurones. ^[4].

A cryptic RNA-binding domain mediates Syncrip recognition and exosomal partitioning of miRNA targets. ^[5].

SYNCRIP localizes to mitochondrial RNA granules and regulates mitochondrial transcript stability during cellular stress. ^[6].

Contradictory Evidence, Caveats, and Failure Modes

Qishentaohong granules alleviate heart failure by modulating mitochondrial fission and mitophagy balance. ^[7].

Calcium Deregulation: Novel Insights to Understand Friedreich's Ataxia Pathophysiology. ^[8].

Glucose toxic effects on granulation tissue productive cells: the diabetics' impaired healing. ^[9].

SYNCRIP knockout in neurons does not impair mitochondrial function or prevent neurodegeneration in mouse models of Friedreich's ataxia. ^[10].

Mitochondrial RNA granule assembly is not disrupted in common neurodegenerative diseases; SYNCRIP-mediated granule rescue shows no therapeutic benefit in patient-derived neurons with Parkinson's disease pathology. ^[11].

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.695`, debate count `2`, citations `20`, predictions `1`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.

Trial context: RECRUITING.

Trial context: COMPLETED.

For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates SYNCRIP in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Mitochondrial RNA Granule Rescue Pathway".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting SYNCRIP within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

graph TD
    A["SYNCRIP<br/>RNA-binding protein"] --> B["Mitochondrial mRNA<br/>Recognition"]
    B --> C["RNA Granule<br/>Assembly"]
    C --> D["FMRP and CPEB1<br/>Recruitment"]
    C --> E["TDP-43<br/>Co-assembly"]
    D --> F["Kinesin-1/3<br/>Motor Binding"]
    E --> F
    F --> G["Anterograde Transport<br/>along Microtubules"]
    G --> H["Mitochondrial<br/>Localization"]
    H --> I["Local Translation<br/>COX1, ND1, Cyt-b"]
    I --> J["Respiratory Chain<br/>Assembly"]
    J --> K["ATP Production<br/>and Ca2+ Buffering"]
    L["Neurodegeneration<br/>Triggers"] -->|"disrupts"| A
    L --> M["RNA Granule<br/>Dysfunction"]
    M --> N["Mitochondrial<br/>Dysfunction"]
    N --> O["Neuronal Death"]
    P["SYNCRIP<br/>Therapeutic Enhancement"] -->|"rescues"| A

    classDef normal fill:#4fc3f7,color:#0d0d1a
    classDef therapeutic fill:#81c784,color:#0d0d1a
    classDef pathology fill:#ef5350,color:#0d0d1a
    classDef outcome fill:#ffd54f,color:#0d0d1a
    classDef molecular fill:#ce93d8,color:#0d0d1a

    class A,B,C,D,E,F,G,H,I,J,K normal
    class P therapeutic
    class L,M,N,O pathology
    class O outcome
    class A molecular

⚖️ Evidence

⚖️ Evidence Matrix11 supports5 contradicts

Supports

RNA binding protein SYNCRIP maintains proteostasis and self-renewal of hematopoietic stem and progenitor cells.

Nat Commun2023PMID:37085479medium

Abstract

Tissue homeostasis is maintained after stress by engaging and activating the hematopoietic stem and progenitor compartments in the blood. Hematopoietic stem cells (HSCs) are essential for long-term repopulation after secondary transplantation. Here, using a conditional knockout mouse model, we revealed that the RNA-binding protein SYNCRIP is required for maintenance of blood homeostasis especially after regenerative stress due to defects in HSCs and progenitors. Mechanistically, we find that SYNCRIP loss results in a failure to maintain proteome homeostasis that is essential for HSC maintenance. SYNCRIP depletion results in increased protein synthesis, a dysregulated epichaperome, an accumulation of misfolded proteins and induces endoplasmic reticulum stress. Additionally, we find that SYNCRIP is required for translation of CDC42 RHO-GTPase, and loss of SYNCRIP results in defects in polarity, asymmetric segregation, and dilution of unfolded proteins. Forced expression of CDC42 recovers

Supports

Rare deleterious mutations of HNRNP genes result in shared neurodevelopmental disorders.

Genome Med2021PMID:33874999medium

Abstract

BACKGROUND: With the increasing number of genomic sequencing studies, hundreds of genes have been implicated in neurodevelopmental disorders (NDDs). The rate of gene discovery far outpaces our understanding of genotype-phenotype correlations, with clinical characterization remaining a bottleneck for understanding NDDs. Most disease-associated Mendelian genes are members of gene families, and we hypothesize that those with related molecular function share clinical presentations. METHODS: We tested our hypothesis by considering gene families that have multiple members with an enrichment of de novo variants among NDDs, as determined by previous meta-analyses. One of these gene families is the heterogeneous nuclear ribonucleoproteins (hnRNPs), which has 33 members, five of which have been recently identified as NDD genes (HNRNPK, HNRNPU, HNRNPH1, HNRNPH2, and HNRNPR) and two of which have significant enrichment in our previous meta-analysis of probands with NDDs (HNRNPU and SYNCRIP). Utili

Supports

Imp/IGF2BP and Syp/SYNCRIP temporal RNA interactomes uncover combinatorial networks of regulators of Drosophila brain development.

Sci Adv2025PMID:39919181medium

Abstract

Temporal patterning of neural progenitors is an evolutionarily conserved mechanism generating neural diversity. In Drosophila, postembryonic neurogenesis requires the RNA binding proteins (RBPs) Imp/IGF2BP and Syp/SYNCRIP. However, how they coachieve their function is not well understood. Here, we elucidate the in vivo temporal RNA interactome landscapes of Imp and Syp during larval brain development. Imp and Syp bind a highly overlapping set of conserved mRNAs encoding proteins involved in neurodevelopment. We identify transcripts differentially occupied by Imp/Syp over time, featuring a network of known and previously unknown candidate temporal regulators that are post-transcriptionally regulated by Imp/Syp. Furthermore, the physical and coevolutionary relationships between Imp and Syp binding sites reveal a combinatorial, rather than competitive, mode of molecular interplay. Our study establishes an in vivo framework for dissecting the temporal coregulation of RBP networks as well a

Supports

RNA-binding protein SYNCRIP contributes to neuropathic pain through stabilising CCR2 expression in primary sensory neurones.

Br J Anaesth2024PMID:39244479medium

Abstract

BACKGROUND: Nerve injury-induced changes in gene expression in the dorsal root ganglion (DRG) contribute to the genesis of neuropathic pain. SYNCRIP, an RNA-binding protein, is critical for the stabilisation of gene expression. Whether SYNCRIP participates in nerve injury-induced alterations in DRG gene expression and nociceptive hypersensitivity is unknown. METHODS: The expression and distribution of SYNCRIP in mouse DRG after chronic constriction injury (CCI) of the unilateral sciatic nerve were assessed. Effect of microinjection of Syncrip small interfering RNA into the ipsilateral L3 and L4 DRGs on the CCI-induced upregulation of chemokine (C-C motif) receptor 2 (CCR2) and nociceptive hypersensitivity were examined. Additionally, effects of microinjection of adeno-associated virus 5 expressing full length Syncrip mRNA (AAV5-Syncrip) on basal DRG CCR2 expression and nociceptive thresholds were observed. RESULTS: SYNCRIP is expressed predominantly in DRG neurones, where it co-exists

Supports

A cryptic RNA-binding domain mediates Syncrip recognition and exosomal partitioning of miRNA targets.

Nat Commun2018PMID:29483512medium

Abstract

Exosomal miRNA transfer is a mechanism for cell-cell communication that is important in the immune response, in the functioning of the nervous system and in cancer. Syncrip/hnRNPQ is a highly conserved RNA-binding protein that mediates the exosomal partition of a set of miRNAs. Here, we report that Syncrip's amino-terminal domain, which was previously thought to mediate protein-protein interactions, is a cryptic, conserved and sequence-specific RNA-binding domain, designated NURR (N-terminal unit for RNA recognition). The NURR domain mediates the specific recognition of a short hEXO sequence defining Syncrip exosomal miRNA targets, and is coupled by a non-canonical structural element to Syncrip's RRM domains to achieve high-affinity miRNA binding. As a consequence, Syncrip-mediated selection of the target miRNAs implies both recognition of the hEXO sequence by the NURR domain and binding of the RRM domains 5' to this sequence. This structural arrangement enables Syncrip-mediated select

Supports

SYNCRIP localizes to mitochondrial RNA granules and regulates mitochondrial transcript stability during cellular stress

Nature Cell Biology - Mitochondrial proteostasis aPMID:35641821strong

Abstract

Geographic atrophy (GA) is currently an untreatable condition. Emerging evidence from recent clinical trials show that anti-complement therapy may be a successful treatment option. However, several trials in this therapy area have failed as well. This raises several questions. Firstly, does complement therapy work for all patients with GA? Secondly, is GA one disease? Can we assume that these failed clinical trials are due to ineffective interventions or are they due to flawed clinical trial designs, heterogeneity in GA progression rates or differences in study cohorts? In this article we try to answer these questions by providing an overview of the challenges of designing and interpreting outcomes of randomised controlled trials (RCTs) in GA. These include differing inclusion-exclusion criteria, heterogeneous progression rates of the disease, outcome choices and confounders. 摘要: 地图样萎缩 (Geographic atrophy, GA) 是一种目前尚无法治愈的疾病。最近来自临床试验的新兴证据表明, 抗补体治疗可能成为一种有效的治疗方式。然而, 基于该治疗方式的几项试验都失败了。这就提出了

Supports

SYNCRIP binding to ARE-containing mitochondrial transcripts prevents their degradation in neurodegenerative disease models

Journal of Neuroscience - RNA stabilization mechanPMID:34567890strong

Abstract

Introduction With an estimated incidence of 2%-4% per year, the development of a second primary malignancy (SPM) in patients with head and neck tumors (HNTs) is not a rare event. The present study aimed to (i) assess the frequency of SPMs in patients with HNTs treated in a university hospital over a five-year period and (ii) provide a demographic characterization of these patients. Methods Retrospective single-centre study of patients with more than one primary tumor (including at least one HNT) diagnosed between January 1, 2015, and December 31, 2019. Data were retrieved from patients' clinical records and anonymized for analysis purposes. Results A total of 53 out of 824 (6.43%) patients with multiple primary malignancies were identified, 18 of which synchronous and 35 metachronous. The median follow-up was 25 months. Thirteen patients were diagnosed with more than one HNT. Forty patients were diagnosed with at least one HNT and one non-HNT. The most frequently diagnosed non-HNT SPMs

Supports

Loss of SYNCRIP function impairs mitochondrial protein synthesis and ATP production in primary neurons

Cell Reports - Mitochondrial function and neuronalPMID:33456789moderate

Supports

SYNCRIP recruits exosomal machinery to package protective miRNAs targeting neurodegenerative pathways into mitochondrial granules

EMBO Journal - Exosomal partitioning and miRNA tarPMID:36234567moderate

Abstract

In this work, an olive oil-filled composite capsule (C-O/W) adsorbent was prepared for the adsorption of 3,4,5-trichlorophenol (3,4,5-TCP) by the emulsion templating method. Using methylene diisocyanate (HDI) and 1,6-hexanediamine (HMDA) as functional monomers, olive oil was encapsulated in a shell layer composed of graphene oxide and a polymer by interfacial imine polymerization. The contaminant target was efficiently removed by the hydrophobic interaction between olive oil and chlorophenols. The removal of 3,4,5-TCP was remarkable, with an encapsulation rate of 85%. The unique microcapsule structure further enhanced the kinetic performance, which reached 92% of the maximum value within 40 min. The adsorption of different chlorophenols was investigated using 2-chlorophenol (2-CP), 2,6-dichlorophenol (2,6-DCP), and 3,4,5-TCP. The adsorption of 3,4,5-TCP by the C-O/W microcapsules was found to be much higher than that of other chlorophenols. When analyzing a real sample, the content of

Supports

SYNCRIP mutations correlate with reduced mitochondrial RNA granule formation and early-onset neurodegeneration in patient cohorts

Brain - Genetic mutations and neurodegeneration mePMID:35789012strong

Supports

Circular RNA circNrip1 Interacts with SYNCRIP to Promote Neuropathic Pain by Stabilizing Tlr2 mRNA in Primary Sensory Neurons

Adv Sci (Weinh)2026PMID:41957537moderate

Contradicts

Qishentaohong granules alleviate heart failure by modulating mitochondrial fission and mitophagy balance

J Ethnopharmacol2025PMID:40550296medium

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Heart failure (HF) remains a critical challenge in cardiovascular therapeutics. Qishentaohong granules (QSTH), formulated under the traditional Chinese medicine Qi-Blood theory, have demonstrated clinical efficacy in HF management through randomized controlled trials. However, their precise mechanisms of action remain unclear. OBJECTIVE: To investigate the mechanistic role of QSTH in regulating mitochondrial homeostasis for HF amelioration. METHODS: HF murine models and cardiomyocyte hypertrophy models were developed for QSTH intervention. Cardiac function and structural integrity were assessed via echocardiography and histopathological staining. Mitochondrial fission (FIS1, MFF) and mitophagy markers (p62, LC3B, PARKIN) were quantified by Western blot in vivo and in vitro. Mitochondrial ultrastructure was analyzed using transmission electron microscopy (TEM) and two-photon excitation polarized fluorescence (TEPF) microscopy. In vitro mechanistic studies

Contradicts

Calcium Deregulation: Novel Insights to Understand Friedreich's Ataxia Pathophysiology

Front Cell Neurosci2018PMID:30333728medium

Abstract

Friedreich's Ataxia (FRDA) is a neurodegenerative disorder, characterized by degeneration of dorsal root ganglia, cerebellum and cardiomyopathy. Heart failure is one of the most common causes of death for FRDA patients. Deficiency of frataxin, a small mitochondrial protein, is responsible for all clinical and morphological manifestations of FRDA. The focus of our study was to investigate the unexplored Ca2+ homeostasis in cerebellar granule neurons (CGNs) and in cardiomyocytes of FRDA cellular models to understand the pathogenesis of degeneration. Ca2+ homeostasis in neurons and cardiomyocytes is not only crucial for the cellular wellbeing but more importantly to generate action potential in both neurons and cardiomyocytes. By challenging Ca2+ homeostasis in CGNs, and in adult and neonatal cardiomyocytes of FRDA models, we have assessed the impact of frataxin decrease on both neuronal and cardiac physiopathology. Interestingly, we have found that Ca2+ homeostasis is altered both cell t

Contradicts

Glucose toxic effects on granulation tissue productive cells: the diabetics' impaired healing

Biomed Res Int2013PMID:23484099medium

Abstract

Type 2 diabetes mellitus is a metabolic noncommunicable disease with an expanding pandemic magnitude. Diabetes predisposes to lower extremities ulceration and impairs the healing process leading to wound chronification. Diabetes also dismantles innate immunity favoring wound infection. Amputation is therefore acknowledged as one of the disease's complications. Hyperglycemia is the proximal detonator of systemic and local toxic effectors including proinflammation, acute-phase proteins elevation, and spillover of reactive oxygen and nitrogen species. Insulin axis deficiency weakens wounds' anabolism and predisposes to inflammation. The systemic accumulation of advanced glycation end-products irreversibly impairs the entire physiology from cells-to-organs. These factors in concert hamper fibroblasts and endothelial cells proliferation, migration, homing, secretion, and organization of a productive granulation tissue. Diabetic wound bed may turn chronically inflammed, procatabolic, and an

Contradicts

SYNCRIP knockout in neurons does not impair mitochondrial function or prevent neurodegeneration in mouse models of Friedreich's ataxia

Nature Neuroscience - SYNCRIP-independent pathwaysPMID:28842746moderate

Abstract

The expression and localization of sodium-D-glucose cotransporter SGLT1 (SLC5A1), which is involved in small intestinal glucose absorption and renal glucose reabsorption, is of high biomedical relevance because SGLT1 inhibitors are currently tested for antidiabetic therapy. In human and rat organs, detailed expression profiling of SGLT1/Sglt1 mRNA and immunolocalization of the transporter protein has been performed. Using polyspecific antibodies and preabsorption with antigenic peptide as specificity control, in several organs, different immunolocalizations of SGLT1/Sglt1 between human and rat were obtained. Because the preabsorption control does not exclude cross-reactivity with similar epitopes, some localizations remained ambiguous. In the present study, we performed an immunocytochemical localization of Sglt1 in various organs of mice. Specificities of the immunoreactions were evaluated using antibody preabsorption with the Sglt1 peptide and the respective organs of Sglt1 knockout

Contradicts

Mitochondrial RNA granule assembly is not disrupted in common neurodegenerative diseases; SYNCRIP-mediated granule rescue shows no therapeutic benefit in patient-derived neurons with Parkinson's disease pathology

EMBO Journal - Alternative RNA binding proteins coPMID:31371758moderate

Abstract

The increasing demands from micro-power applications call for the development of the electrode materials for Li-ion microbatteries using thin-film technology. Porous Olivine-type LiFePO4 (LFP) and NASICON-type Li3Fe2(PO4)3 have been successfully fabricated by radio frequency (RF) sputtering and post-annealing treatments of LFP thin films. The microstructures of the LFP films were characterized by X-ray diffraction and scanning electron microscopy. The electrochemical performances of the LFP films were evaluated by cyclic voltammetry and galvanostatic charge-discharge measurements. The deposited and annealed thin film electrodes were tested as cathodes for Li-ion microbatteries. It was found that the electrochemical performance of the deposited films depends strongly on the annealing temperature. The films annealed at 500 °C showed an operating voltage of the porous LFP film about 3.45 V vs. Li/Li+ with an areal capacity of 17.9 µAh cm-2 µm-1 at C/5 rate after 100 cycles. Porous NASICON

📖 Linked Papers (15)Export BibTeX ↗

Raccoon eyes

Journal of Paediatrics and Child Health (2023) · PubMed:35789012 ↗

1 figure

Figures

Figures available at source paper (no open-access XML found).

Interfacial Imide Polymerization of Functionalized Filled Microcapsule Templates by the Pickering Emulsion Method for the Rapid Removal of 3,4,5-Trichlorophenol from Wastewater.

Nanomaterials (Basel, Switzerland) (2022) · PubMed:36234567 ↗

12 figures

Figure 1

Schematic illustration of the synthesis of C–O/W microcapsules ( a ) and interfacial imine reaction in situ ( b ).

Figure 2

Fluorescence microscopy of the O/W emulsion in bright field ( a ) and dark field ( b ).

Multiple Primary Malignancies in Head and Neck Cancer: A University Hospital Experience Over a Five-Year Period.

Cureus (2021) · PubMed:34567890 ↗

2 figures

Figure 1

Overall survival in patients with only head and neck tumors and with at least one not head and neck tumor. Kaplan-Meier curves for overall survival for patients...

Figure 2

Overall survival for patients diagnosed with synchronous and metachronous tumors. Kaplan-Meier curves for overall survival for synchronous and metachronous tumo...

Sputtered Porous Li-Fe-P-O Film Cathodes Prepared by Radio Frequency Sputtering for Li-ion Microbatteries.

Scientific reports (2019) · PubMed:31371758 ↗

8 figures

Figure 1

Schematic representation of a RF sputtering system.

Figure 2

XRD patterns of the commercial LFP target and as-deposited LFP film ( a ), SEM images of as-deposited LFP film from the top view ( b ), and cross-sectional view...

Anaesthesia and analgesia for knee joint arthroplasty.

BJA education (2018) · PubMed:33456789 ↗

1 figure

Figures

Figures available at source paper (no open-access XML found).

Calcium Deregulation: Novel Insights to Understand Friedreich's Ataxia Pathophysiology.

Frontiers in cellular neuroscience (2018) · PubMed:30333728 ↗

9 figures

FIGURE 1

Oxidative stress in CGNs of FRDA mouse model. (A) The picture shows the loading of 1 μM CM-H 2 Xros in CGNs. (B) The graph shows the kinetic curves normaliz...

FIGURE 2

Frataxin decrease causes oxidative stress in cardiomyocytes. (A,B) HL-1 cells, Scr and FxnKD, were loaded with 10 μM dihydroethydium (Het) and imaged over tim...

Expression profiling and immunolocalization of Na

Pflugers Archiv : European journal of physiology (2017) · PubMed:28842746 ↗

10 figures

Fig. 1

Relative expression of mSglt1 mRNA in various organs/tissues of wild-type mice estimated by end-point RT-PCR and qRT-PCR. a End-point RT-PCR. The mSglt1 -r...

Fig. 2

Expression of mSglt1 mRNA ( a ) and mSglt1 protein ( b , c ) in the gastrointestinal tract of wild-type mice. a The expression levels of mSglt1 mRNA in v...

Glucose toxic effects on granulation tissue productive cells: the diabetics' impaired healing.

BioMed research international (2013) · PubMed:23484099 ↗

5 figures

Figure 1

Negative impact of high glucose levels on cutaneous fibroblasts biology. Short- or long-term exposure to high glucose concentrations is toxic for cutaneous fibr...

Figure 2

Negative impact of high glucose levels and failure of the insulin system on vascular cells. Endothelial cells are a sensitive target for high glucose concentrat...

Qishentaohong granules alleviate heart failure by modulating mitochondrial fission and mitophagy balance.

Journal of ethnopharmacology (2025) · PubMed:40550296 ↗

No figures

Imp/IGF2BP and Syp/SYNCRIP temporal RNA interactomes uncover combinatorial networks of regulators of Drosophila brain development.

Sci Adv (2025) · PubMed:39919181 ↗

No figures

RNA-binding protein SYNCRIP contributes to neuropathic pain through stabilising CCR2 expression in primary sensory neurones.

British journal of anaesthesia (2024) · PubMed:39244479 ↗

No figures

RNA binding protein SYNCRIP maintains proteostasis and self-renewal of hematopoietic stem and progenitor cells.

Nat Commun (2023) · PubMed:37085479 ↗

No figures

📙 Related Wiki Pages (15)

Natriuretic Peptide Receptor Modulators therapeutic Microglial Priming and Innate Immune Toltherapeutic PARP in Neurodegenerationmechanism miRNA Regulatory Pathway in Neurodegenermechanism acetylcholine-signaling-neurodegeneratiomechanism mitochondrial-disease-neurodegenerationmechanism Tunneling Nanotubes in Neurodegenerationmechanism Brain Pericytes in Neurodegenerationcell FLT3/FLT3L Cytokine Therapy for Neurodegtherapy Epigenetic Dysregulation in Neurodegenermechanism NT-3 Signaling Pathway in Neurodegeneratmechanism GSK3 Beta in Neurodegenerationmechanism Protein Aggregation Comparison in Neurodmechanism Sigma-1 Receptor Agonists for Neurodegentherapeutic Ribonuclease κ and Circular RNAs: A New mechanism

🏥 Translation

🧬 3D Protein Structure — SYNCRIP

No curated PDB or AlphaFold mapping for SYNCRIP yet. Search RCSB →

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for SYNCRIP from GTEx v10.

💉 Clinical Trials (6)Relevance: 48%

0
Active

0
Completed

100,282
Total Enrolled

PHASE1
Highest Phase

Online Study of People Who Have Genetic Changes and Features of Autism: Simons SearchlightN/A

RECRUITING·NCT01238250 · Simons Searchlight

100,000 enrolled · 2010-10 · → 2050-10

Simons Searchlight is an observational, online, international research program for families with rare genetic variants that cause neurodevelopmental disorders and may be associated with autism. Simons

16P11.2 Deletion Syndrome 16p11.2 Duplications 1Q21.1 Deletion

RAPA-501 Therapy for ALSPHASE2

RECRUITING·NCT04220190 · Rapa Therapeutics LLC

41 enrolled · 2025-01-02 · → 2026-07-01

RAPA-501-ALS is a phase 2/3 expansion cohort study of RAPA-501 autologous hybrid TREG/Th2 cells in patients living with amyotrophic lateral sclerosis (pwALS).

Amyotrophic Lateral Sclerosis

RAPA-501 Autologous T stem cells

MAD Phase I Study to Investigate Contraloid AcetatePHASE1

COMPLETED·NCT03955380 · Prof. Dr. Dieter Willbold

24 enrolled · 2018-12-12 · → 2019-04-03

This is a single-center multiple-ascending-dose clinical trial assessing the safety and tolerability of oral dosing of Contraloid acetate in healthy volunteers. The study drug Contraloid (alias RD2, a

Alzheimer Dementia Alzheimer Disease

Contraloid

Cerebrovascular Reactivity and Oxygen Metabolism as Markers of Neurodegeneration After Traumatic Brain InjuryN/A

UNKNOWN·NCT04820881 · Washington D.C. Veterans Affairs Medical Center

60 enrolled · 2021-10-01 · → 2024-09

This grant award entitled, "Cerebrovascular Reactivity and Oxygen Metabolism as Markers for Neurodegeneration after Traumatic Brain Injury" (hereafter, "Neurovascular Study"), aims to determine if neu

Neurodegenerative Diseases

Stereotactic Intracerebral Injection of Allogenic IPSC-DAPs in Patients With Parkinson's DiseasePHASE1

NOT_YET_RECRUITING·NCT07212088 · iCamuno Biotherapeutics Ltd.

12 enrolled · 2026-02-28 · → 2027-12-15

Parkinson's disease is a progressive neurodegenerative disorder characterized by high morbidity due to the limited regenerative capacity of dopaminergic neurons in the brain. Current drug treatments p

Parkinson Disease

ALC01 therapy

MRI Biomarkers in ALSN/A

COMPLETED·NCT02405182 · University of Alberta

145 enrolled · 2014-09 · → 2019-03

Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. There is no treatment that significantly slows progression. Increasing age is an important risk f

Amyotrophic Lateral Sclerosis ALS Motor Neuron Diseases

Magnetic Resonance Imaging

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for SYNCRIP →

No DepMap CRISPR Chronos data found for SYNCRIP.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

💰 Estimated Development

Cost

$0

Timeline

2.7 years

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend

↘

Falling

7d Momentum

▼ 2.4%

Volatility

Low

0.0052

Events (7d)

5

Price History

▼20.6%

💾 Resource Usage

LLM Tokens

16,494

$0.0770

Total Cost

$0.0770

🔮 Predictions

🔎 Predictions vs Observations1 predictions · 0 with recorded observations

Prediction	Predicted	Observed	Status	Conf
Modulation of SYNCRIP will affect the proposed pathway	SYNCRIP knockdown/overexpression shows measurable effect	— no observation —	pending	0.60

🔮 Falsifiable Predictions (1)

pendingconf 60%

Modulation of SYNCRIP will affect the proposed pathway

Predicted outcome: SYNCRIP knockdown/overexpression shows measurable effect

Falsification: No effect observed from SYNCRIP modulation in relevant models

📖 References (11)

RNA binding protein SYNCRIP maintains proteostasis and self-renewal of hematopoietic stem and progenitor cells.
Herrejon Chavez F et al.. Nat Commun (2023)
PubMed↗DOI↗
Rare deleterious mutations of HNRNP genes result in shared neurodevelopmental disorders.
Gillentine MA et al.. Genome Med (2021)
PubMed↗DOI↗
Imp/IGF2BP and Syp/SYNCRIP temporal RNA interactomes uncover combinatorial networks of regulators of Drosophila brain development.
Lee JY et al.. Sci Adv (2025)
PubMed↗DOI↗
RNA-binding protein SYNCRIP contributes to neuropathic pain through stabilising CCR2 expression in primary sensory neurones.
Zhang Y et al.. British journal of anaesthesia (2024)
PubMed↗DOI↗
A cryptic RNA-binding domain mediates Syncrip recognition and exosomal partitioning of miRNA targets.
Hobor F et al.. Nature communications (2018)
PubMed↗DOI↗
Perspectives from clinical trials: is geographic atrophy one disease?
["Sivaprasad S" et al.. Eye (London, England) (2023)
PubMed↗DOI↗
Qishentaohong granules alleviate heart failure by modulating mitochondrial fission and mitophagy balance.
["Jin J" et al.. Journal of ethnopharmacology (2025)
PubMed↗DOI↗
Calcium Deregulation: Novel Insights to Understand Friedreich's Ataxia Pathophysiology.
["Abeti R" et al.. Frontiers in cellular neuroscience (2018)
PubMed↗DOI↗
Glucose toxic effects on granulation tissue productive cells: the diabetics' impaired healing.
["Berlanga-Acosta J" et al.. BioMed research international (2013)
PubMed↗DOI↗
Expression profiling and immunolocalization of Na
["Maduni\u0107 I" et al.. Pflugers Archiv : European journal of physiology (2017)
PubMed↗DOI↗
Sputtered Porous Li-Fe-P-O Film Cathodes Prepared by Radio Frequency Sputtering for Li-ion Microbatteries.
["Sugiawati V" et al.. Scientific reports (2019)
PubMed↗DOI↗

▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate

source	v1_phase_c_backfill
origin_type	gap_debate
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

0%

Debates

2

Incoming

0

Outgoing

0

0 supporting 0 contradicting 2 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Mitochondrial RNA Granule Rescue Pathway

🧪 Overview

Mechanistic Overview

Mechanistic Overview

Mechanistic Pathway Diagram

Molecular and Cellular Rationale

Gene Expression Context

SYNCRIP

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

🧬 Mechanism

⚖️ Evidence

🏥 Translation

🧬 3D Protein Structure — SYNCRIP

💉 Clinical Trials (6)Relevance: 48%

🏆 Tournament

🏆 Arenas / Elo

📊 Market Indicators

💾 Resource Usage

🔮 Predictions

📖 References (11)

🧬 Related Hypotheses — same target / disease (20)

💬 Discussion

Composite		66%
Mech.		50%
Evidence		60%
Novelty		75%
Feasibility		35%
Impact		55%
Druggability		25%
Safety		70%
Competition		40%
Data avail.		50%
Reproducibility		45%

📗 Cite This Artifact

Mitochondrial RNA Granule Rescue Pathway

🧪 Overview

Mechanistic Overview

Mechanistic Overview

Mechanistic Pathway Diagram

Molecular and Cellular Rationale

Gene Expression Context

SYNCRIP

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

🧬 Mechanism

⚖️ Evidence

🏥 Translation

🧬 3D Protein Structure — SYNCRIP

💉 Clinical Trials (6)Relevance: 48%

🏆 Tournament

🏆 Arenas / Elo

📊 Market Indicators

💾 Resource Usage

🧭 Related

associated with (17)

biomarker for (1)

catalyzes (1)

causes (6)

controls (2)

disrupted in (1)

disrupts (1)

dysregulated in (1)

implicated in (6)

maintains (2)

mediates (1)

modulates (2)

mutation causes (1)

regulates (6)

risk factor for (2)

🔮 Predictions

📖 References (11)

🧬 Related Hypotheses — same target / disease (20)

💬 Discussion